ZURICH/SYDNEY (Reuters) -Vifor Pharma's shares surged more than 15% in early trading on Monday after the Swiss drugmaker and Australia's CSL both confirmed they were talking about a potential merger.
CSL shares are down roughly 40% since acquiring Vifor in August 2022, an iron deficiency and kidney disease business and the largest acquisition in its history. However, several other factors have ...
BRUSSELS, July 22 (Reuters) - EU antitrust regulators on Monday accepted Australian group CSL (CSL.AX), opens new tab unit Vifor Pharma's concessions to address potential anti-competitive behaviour ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results